Hospitals & Doctors
Premium Hospitals Selected · Senior Experts Gathered, For Your Reassuring Health Journey
LU Peihua
Languages:
Dual China-US License | Hematologic Oncology | CAR-T
Dr. Lu Peihua serves as the Executive Medical Director of Beijing Ludaopei Hematology Hospital and Dean of the Beijing Ludaopei Hematology Research Institute (Tsinghua University School of Medicine).
She graduated from Peking University Medical School and completed her hematology and oncology fellowship at Stanford University Medical Center with distinction.
During her training, she received two prestigious NIH awards including a Postdoctoral Research Award and a Physician Scientist Award (K08).
Her groundbreaking research on Cytokine Induced Killer (CIK) Cells was later introduced to clinical practice in China.
In 2012, she was recognized as an Outstanding Hematologist and Oncologist by the American Consumer Association.
Returning to China in 2015, she brings extensive expertise in CAR-T cell immunotherapy, lymphoma, myeloma, and leukemia, holding board certifications in both hematology and oncology in the United States, as well as a Chinese medical practice license with US prescribing authority.
11+ Years of CAR-T Experience
500+ CD7 CAR-T Cases
1,600+ Annual Transplants
5 ASH Oral Presentations
Focus on Disease Treatment & Therapeutic Methods
| Disease | Treatment Method | Advantage |
|---|---|---|
| Lymphoma | Chemotherapy + Targeted Therapy + Immunotherapy + CAR-T | Personalized risk-stratified treatment with international novel drugs |
| Multiple Myeloma | Targeted Drugs + Immunotherapy + HSCT | BCMA CAR-T achieving ~50% complete remission rate |
| Acute Leukemia | Chemotherapy + CAR-T + HSCT | Leading CD7 CAR-T technology with 90% CR rate |
| Refractory Hematologic Malignancies | Novel Drug Clinical Trials + Universal CAR-T | Extensive novel drug experience with dual China-US license |
Target Patient Populations
- Patients with lymphoma.
- Patients with multiple myeloma.
- Patients with acute or chronic leukemia.
- Patients with relapsed or refractory hematologic malignancies.
- Patients requiring CAR-T immunotherapy or hematopoietic stem cell transplantation.
Career Path
Career Milestones
Professional Memberships
Hematology Committee, Chinese Non-Government Medical Institutions Association
Biotechnology Committee, Chinese Non-Government Medical Institutions Association
China Marrow Donor Program
Anti-Leukemia Alliance, Chinese Society of Clinical Oncology (CSCO)
Hematology Translational Medicine Committee, Chinese Anti-Cancer Association
American Society of Hematology (ASH)
Clinical Highlights
Over 500 clinical cases of CD7 CAR-T therapy.
Over 1,600 hematopoietic stem cell transplants performed annually, ranking first in the China Marrow Donor Program for six consecutive years.
Five oral presentations selected for the 2020 ASH Annual Meeting, with multiple research studies achieving international recognition.
Presented the latest findings on universal CAR-T therapy for T-ALL at the 2025 EHA Annual Meeting.
Presented innovative findings on CD7 CAR-T bridging transplantation at the 2026 EBMT Annual Meeting.
Published multiple research papers in international medical journals, including Blood.
Academic Achievements
11+ Years
CAR-T Treatment Experience
500+ Cases
CD7 CAR-T Clinical Cases
1,600+
Annual Transplants
5 Presentations
ASH Oral Presentations
Professional Memberships
- NIH Postdoctoral Research Award
- NIH Physician Scientist Award (K08)
Representative Publications
Nanobody-based Naturally Selected CD7-Targeted CAR-T Cell Therapy for AML
2025
Lu Peihua et al.
Multicenter Study of Universal CD7 CAR-T (CTD402) for R/R T-ALL/LBL
2025 / 2026
EHA
Application of CD7 CAR-T Bridging Transplantation in Mixed Phenotype Acute Leukemia
2026
EBMT
Efficacy of Anti-BCMA CAR-T Cells in Multiple Myeloma
2020
ASH
Feasibility and Safety of STAR-T Cell Therapy for R/R B-ALL
2020
ASH
Academic Exchanges
- Invited to deliver oral presentations at the American Society of Hematology (ASH) Annual Meeting on multiple occasions.
- Invited speaker at the European Hematology Association (EHA) Annual Meeting.
- Presented research at the European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting.
- Established collaborative alliances with multiple international hospitals, conducting remote consultations and academic exchanges.
Get Your Free No-obligation Medical
Consultation Now